Company Overview and News

2
IRDAI#39;s move to allow PEs as promoters piques their interest in insurance firms

2018-06-01 moneycontrol
Private equity (PE) major Warburg Pincus is reportedly buying a 26 percent stake of Legal & General, the foreign joint venture partner in IndiaFirst Life Insurance. According to a report, the PE major will be paying Rs 710 crore for the stake, valuing the insurer at Rs 2,730 crore.
EXIDEIND SSREY EXQDY KMBKY KOTAKBANK 500247 500086 SBAZ SSREF

0
Exide Industries (EXQDY) Investor Presentation - Slideshow

2018-05-29 seekingalpha
The following slide deck was published by Exide Industries Ltd. ADR in conjunction with this event.
EXQDY EXIDEIND 500086

2
This week in Auto: When recall becomes a bad word

2018-05-12 moneycontrol
Eicher Motors, Exide Industries and Apollo Tyres announced their fourth quarter financial results this week as the automotive industry entered the earnings season. Net profit of all three companies missed street estimates when compared to a Reuters poll of analyst expectations.
505200 EXIDEIND ECQRY EXQDY 500877 7269 APOLLOTYRE AYRQY 500086 EICHERMOT

16
Exide shares extend gains on robust net profit

2018-05-08 thehindubusinessline
Goldman Sachs has raised its FY19-20 revenue estimates by an average of 2.4 per cent to factor in robust volumes and lead prices.
EXIDEIND DB MS.PRE 512068 MS.PRF MS.PRG MS.PRA DECNGOLD EXQDY MS.PRI MS.PRK MS 500086

12
Exide Industries hits new 52-week high; Investec maintains buy with target Rs 280

2018-05-08 moneycontrol
Exide Industries gained further ground on Tuesday post robust numbers declared by the company for the quarter ended Mach 2018.
EXIDEIND EXQDY MS.PRI MS.PRK MS.PRE MS.PRF MS.PRG MS 500086 MS.PRA

0
Exide Q4 profit rises 15.4% at Rs189.56 crore

2018-05-07 livemint
New Delhi: Battery maker Exide Industries on Monday reported 15.4% increase in standalone net profit at Rs189.56 crore for the fourth quarter ended on 31 March 2018.
EXIDEIND EXQDY 500086

0
Exide Industries touches 52-week high on robust Q4 numbers

2018-05-07 moneycontrol
Shares of Exide Industries ended with a gain of 5.5 percent, touching 52-week high of Rs 268.50 on the back of strong March quarter numbers.
EXIDEIND EXQDY 500086

0
Exide Industries Q4 profit grows 15.4% YoY to Rs 189 crore, misses estimates

2018-05-07 moneycontrol
Exide Industries, India’s largest battery storage company, posted a 15.4 percent year-on-year increase in net profit at Rs 189.56 crore in the fourth quarter of FY18. In Q4FY17, the net profit was Rs 164.26 crore.
EXIDEIND EXQDY 500086

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...